Search Results for: Respiratory

2697 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CTSD and INS cathepsin D insulin
  • Collagen degradation
  • Metabolism of Angiotensinogen to Angiotensins
  • MHC class II antigen presentation
  • Neutrophil degranulation
  • Estrogen-dependent gene expression
  • Regulation of gene expression in beta cells
  • Insulin processing
  • Insulin processing
  • Synthesis, secretion, and deacylation of Ghrelin
  • Regulation of insulin secretion
  • COPI-mediated anterograde transport
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Amyloid fiber formation
  • Insulin Human
  • Insulin Pork
  • S-Methylcysteine
  • 1h-Benoximidazole-2-Carboxylic Acid
  • N-Aminoethylmorpholine
  • 5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID
  • CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE
  • Zinc
  • M-Cresol
  • Myristic acid
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
  • Maturity onset diabetes of the young (MODY)
  • Type I diabetes mellitus
  • Permanent neonatal diabetes mellitus (PNDM)
CTSD and NLGN3 cathepsin D neuroligin 3
  • Collagen degradation
  • Metabolism of Angiotensinogen to Angiotensins
  • MHC class II antigen presentation
  • Neutrophil degranulation
  • Estrogen-dependent gene expression
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Insulin Human
  • Insulin Pork
  • S-Methylcysteine
  • 1h-Benoximidazole-2-Carboxylic Acid
  • N-Aminoethylmorpholine
  • 5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID
  • CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
CTSE and INS cathepsin E insulin
  • MHC class II antigen presentation
  • Regulation of gene expression in beta cells
  • Insulin processing
  • Insulin processing
  • Synthesis, secretion, and deacylation of Ghrelin
  • Regulation of insulin secretion
  • COPI-mediated anterograde transport
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Amyloid fiber formation
  • Zinc
  • M-Cresol
  • Myristic acid
  • Maturity onset diabetes of the young (MODY)
  • Type I diabetes mellitus
  • Permanent neonatal diabetes mellitus (PNDM)
CYB561 and LMNA cytochrome b561 lamin A/C
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
CYBA and UPF2 cytochrome b-245 alpha chain UPF2 regulator of nonsense mediated mRNA decay
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • WNT5:FZD7-mediated leishmania damping
  • Regulation of expression of SLITs and ROBOs
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Dextromethorphan
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
CYBA and APPBP2 cytochrome b-245 alpha chain amyloid beta precursor protein binding protein 2
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • WNT5:FZD7-mediated leishmania damping
  • Dextromethorphan
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
CYBA and RCHY1 cytochrome b-245 alpha chain ring finger and CHY zinc finger domain containing 1
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • WNT5:FZD7-mediated leishmania damping
  • Translesion Synthesis by POLH
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Dextromethorphan
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
CYBA and PSMA3 cytochrome b-245 alpha chain proteasome 20S subunit alpha 3
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • WNT5:FZD7-mediated leishmania damping
  • Activation of NF-kappaB in B cells
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • ER-Phagosome pathway
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Vpu mediated degradation of CD4
  • Vif-mediated degradation of APOBEC3G
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Separation of Sister Chromatids
  • FCERI mediated NF-kB activation
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Regulation of ornithine decarboxylase (ODC)
  • ABC-family proteins mediated transport
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Asymmetric localization of PCP proteins
  • Degradation of AXIN
  • Degradation of DVL
  • Hedgehog ligand biogenesis
  • Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'on' state
  • Regulation of RAS by GAPs
  • TNFR2 non-canonical NF-kB pathway
  • NIK - noncanonical NF-kB signaling
  • Defective CFTR causes cystic fibrosis
  • MAPK6/MAPK4 signaling
  • UCH proteinases
  • Ub-specific processing proteases
  • CDT1 association with the CDC6:ORC:origin complex
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Regulation of PTEN stability and activity
  • Neddylation
  • Regulation of expression of SLITs and ROBOs
  • Interleukin-1 signaling
  • Negative regulation of NOTCH4 signaling
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Dextromethorphan
  • (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE
  • Phenethyl Isothiocyanate
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
CYBA and RBPMS cytochrome b-245 alpha chain RNA binding protein, mRNA processing factor
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • WNT5:FZD7-mediated leishmania damping
  • Dextromethorphan
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
CYBA and MDFI cytochrome b-245 alpha chain MyoD family inhibitor
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • WNT5:FZD7-mediated leishmania damping
  • Dextromethorphan
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
CYBB and IQGAP1 cytochrome b-245 beta chain IQ motif containing GTPase activating protein 1
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Nephrin family interactions
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • RHO GTPases activate IQGAPs
  • MAP2K and MAPK activation
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Dextromethorphan
  • Artenimol
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
CYP2C8 and ECSIT cytochrome P450 family 2 subfamily C member 8 ECSIT signaling integrator
  • Xenobiotics
  • CYP2E1 reactions
  • Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)
  • Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)
  • Biosynthesis of maresin-like SPMs
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Complex I biogenesis
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 cascade initiated on plasma membrane
  • Isoniazid
  • Palmitic Acid
  • (5R)-5-(4-{[(2R)-6-HYDROXY-2,5,7,8-TETRAMETHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL]METHOXY}BENZYL)-1,3-THIAZOLIDINE-2,4-DIONE
CYP2C9 and ECSIT cytochrome P450 family 2 subfamily C member 9 ECSIT signaling integrator
  • Xenobiotics
  • CYP2E1 reactions
  • Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)
  • Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)
  • Biosynthesis of maresin-like SPMs
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Complex I biogenesis
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 cascade initiated on plasma membrane
  • 4-Hydroxy-3-[(1s)-3-Oxo-1-Phenylbutyl]-2h-Chromen-2-One
  • Heme C
  • Diacerein
  • Benzbromarone
CYP2C18 and ECSIT cytochrome P450 family 2 subfamily C member 18 ECSIT signaling integrator
  • Xenobiotics
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Complex I biogenesis
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 cascade initiated on plasma membrane
  • 4-METHYL-N-METHYL-N-(2-PHENYL-2H-PYRAZOL-3-YL)BENZENESULFONAMIDE
DACH1 and SOX3 dachshund family transcription factor 1 SRY-box transcription factor 3
  • Deactivation of the beta-catenin transactivating complex
  • Septo-optic dysplasia
  • Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
  • 46,XX disorders of sex development (Disorders of gonadal development), including: Ovotesticular DSD; Testicular DSD; Ovarian dysgenesis
  • Syndromic X-linked mental retardation, including: Turner type (MRXST); Siderius type (MRXSSD) ; Cabezas type (MRXC); Raymond type (MRXSR); Type10 (MRXS10); Type14 (MRXS14); Mental retardation with isolated growth hormone deficiency (MRGH)
DACH1 and SOX4 dachshund family transcription factor 1 SRY-box transcription factor 4
  • Deactivation of the beta-catenin transactivating complex
DACH1 and RNF14 dachshund family transcription factor 1 ring finger protein 14
  • Antigen processing: Ubiquitination & Proteasome degradation
DACH1 and AURKA dachshund family transcription factor 1 aurora kinase A
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Regulation of PLK1 Activity at G2/M Transition
  • SUMOylation of DNA replication proteins
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • AURKA Activation by TPX2
  • Interaction between PHLDA1 and AURKA
  • Phosphonothreonine
  • AT9283
  • CYC116
  • Alisertib
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • 8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-one
  • 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
  • 1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}urea
  • 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
  • N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
  • N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
  • 2-(1H-pyrazol-3-yl)-1H-benzimidazole
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • MLN8054
DACH1 and MYC dachshund family transcription factor 1 MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Nadroparin
  • Choriocarcinoma
  • Penile cancer
  • Burkitt lymphoma
  • Oral cancer
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Multiple myeloma
  • Small cell lung cancer
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Osteosarcoma
  • Kaposi's sarcoma
  • Laryngeal cancer
  • Breast cancer
  • Ovarian cancer
DACH1 and STK11 dachshund family transcription factor 1 serine/threonine kinase 11
  • AMPK inhibits chREBP transcriptional activation activity
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • Regulation of TP53 Activity through Phosphorylation
  • FOXO-mediated transcription of cell death genes
  • Peutz-Jeghers syndrome
  • Pancreatic cancer

Page 43 out of 135 pages